TCL1A and lymphoma: Additionally, in vivo, the anti-oxidant myricetin significantly reduces lymphoma xenografts and TCL1 expression Overall, these findings suggest that TCL1 is a novel client protein of HSP70 and that the chemical inhibition of HSP70 could represent an indirect way to inhibit TCL1 through its degradation.